NeuroBo Pharmaceuticals’ DA-1726 shows weight loss efficacy in preclinical tests

NeuroBo Pharmaceuticals announced that DA-1726, a novel oxyntomodulin – OXM – analogue functioning as a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, had been shown to elicit superior weight loss efficacy compared to Semaglutide and Tirzepatide in preclinical testing. This data was presented at the American Diabetes Association’s 83rd Scientific Sessions June 23-26. Researchers believe that DA-1726 will have similar, superior weight loss effects in humans utilizing its mechanism of action. In a comparative preclinical mouse study with GLP1R/glucose-dependent insulinotropic polypeptide receptor dual agonist, Tirzepatide, DA-1726 showed similar efficacy on weight loss, despite consuming more food. However, DA-1726 was more efficacious in improving plasma metabolic parameters compared to TIR. Taken together, these data suggest that DA-1726 will have effective weight loss and glycemic control in humans. During the second half of this year, NeuroBo’s goal is to advance DA-1726 through the IND process. Assuming acceptance by the FDA, the company plans to initiate a phase 1a safety study during the first half of 2024 and anticipates a data readout in the second half of 2024.